Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2021-08-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司关于继续承办中源协和生命医学奖的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company 中源协和细胞基因工程股份有限公司 regarding the continuation of sponsoring the 中源协和生命医学奖 (Zhongyuan Xiehe Life Medicine Award). It details the board meeting resolution, cooperation agreements, donation amounts, and the impact on the company. The document is a formal announcement of a corporate social responsibility activity and related agreements, not a financial report or regulatory filing. It does not contain financial statements, earnings data, or management discussion of financial results. It is also not a proxy, voting result, or governance report. The document length is 3416 characters, relatively short, and it is an announcement of a corporate action rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2021-08-29 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易限售股上市流通的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the unlocking and circulation of restricted shares related to a non-public issuance of shares for asset purchase and fundraising by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes specific dates, share quantities, shareholder commitments, and compliance with regulatory requirements. The content focuses on the verification and approval of restricted shares becoming tradable, which is a capital/financing update related to share issuance and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing but a specialized advisory opinion on a capital transaction and share circulation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 2616 characters, which is sufficient for a substantive update rather than a mere announcement.
2021-08-23 Chinese
中源协和细胞基因工程股份有限公司非公开发行限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the listing and circulation of restricted shares (限售股上市流通公告) for a specific company, including information about the number of shares, lock-up periods, shareholder commitments, and changes in share capital. It references regulatory approval from the China Securities Regulatory Commission and includes a verification opinion from an independent financial advisor. The document does not contain financial statements or performance data but focuses on share circulation and capital structure changes related to restricted shares becoming tradable. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2021-08-23 Chinese
中源协和细胞基因工程股份有限公司关于控股股东自愿性信息披露公告
Major Shareholding Notification Classification · 95% confidence The document is a voluntary information disclosure announcement by a controlling shareholder regarding a reduction in shareholding. It details the shareholder's stock sale, compliance with disclosure rules, and corrective actions taken. There is no financial report, earnings data, or meeting materials. The content fits the category of Major Shareholding Notification, as it reports changes in significant share ownership levels and related compliance information.
2021-07-09 Chinese
信永中和会计师事务所对《关于中源协和细胞基因工程股份有限公司2020年年度报告的信息披露监管工作函》的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an auditing firm (ShineWing Certified Public Accountants) to a regulatory inquiry from the Shanghai Stock Exchange regarding the company's 2020 Annual Report disclosures. It includes extensive audit procedures, financial data, and management explanations related to the 2020 fiscal year. The content focuses on audit opinions, financial statement items such as cash, receivables, and prepayments, and compliance with accounting standards. The document is lengthy (15,000 characters) and contains substantive financial data and audit findings, not merely an announcement or certification. Therefore, it is an Audit Report / Information document, as it is a standalone audit report responding to regulatory questions about the annual report, but it is not the full Annual Report itself.
2021-07-09 Chinese
中源协和细胞基因工程股份有限公司关于对上海证券交易所2020年年度报告的信息披露监管工作函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response from a company to a regulatory inquiry by the Shanghai Stock Exchange regarding its 2020 Annual Report. It contains extensive financial disclosures, including detailed explanations about cash and financial assets, investment income, use of raised funds, project progress, receivables, prepayments, and auditor opinions. The document references the 2020 Annual Report multiple times and includes auditor procedures and opinions related to the annual financial statements. The length (15,000 characters) and depth of financial detail indicate this is not a brief announcement or certification but a substantive report or part of an annual report. The document is not a transcript, call, or presentation, nor is it a proxy or voting result. It is clearly related to the annual financial reporting and audit. Therefore, the most appropriate classification is Annual Report (10-K).
2021-07-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.